DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for frontotemporal dementia — screening already-approved drugs against its 34-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFrontotemporal dementia maps to a 34-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for frontotemporal dementia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
angiogenin (ANG) — ANG is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet -drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4AOH · 1.041 Å · ligand D(-)-TARTARIC ACID (TAR). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Revista médica de Chile · 2009 · 4 citations · open access
Demencia frontotemporal: Experiencia clínica
AbstractBACKGROUND: Front temporal dementias (FTD) are neurodegenerative disorders characterized by alterations in behavior, affection and language, with relative sparing of episodic memory. There are three major forms of FTD: the frontal or behavioral form, progressive non-fluent aphasia and semantic dementia (that may begin as a fluent progressive aphasia). AIM: To report a retrospective clinical experience of patients with frontotemporal dementia. MATERIAL AND METHODS: Review of 3,700 records of neuropsychological assessments of patients with behavioral disturbances, studied between 1981 and 2008. Of these, 63 patients (59% females) complied with the criteria for frontotemporal dementia. RESULTS: There were 47 cases with the frontal variant, four with non-fluent progressive aphasia and six with fluent progressive aphasias (2 evolved to semantic dementia). The mean age of onset was 60+/-11 years. There were no familiar cases of FTD. CONCLUSIONS: It is clinically difficult to diagnose FTD, since evaluation of attitude or language is required. In addition to structural images, functional images were helpful in some cases, but the definitive diagnosis is anatomical.
Journal of Education Health and Sport · 2024 · 1 citations · open access
Frontotemporal Dementia: A Clinical Review
AbstractFrontotemporal dementia is a disease in which atrophic changes occur in the frontal lobes and frontal temporal lobes of the brain. Frontotemporal dementias are a clinically, neuroanatomically and pathologically diverse group of diseases that collectively constitute an important cause of young-onset dementia. The most common form of frontotemporal dementia is the so-called behavioral variant of frontotemporal dementia. Underlying these pathological changes is the degeneration of nerve cells (i.e. neurons), which occurs through the accumulation of abnormal proteins inside them. Therefore, the review of current studies in the subject of Frontotemporal dementia was conducted in order to access possible risk factors and new ways of management and treatment of this complex disease.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
